Skip to main content
Premium Trial:

Request an Annual Quote

Verdezyne to Synthesize Genes for Syngenta

NEW YORK (GenomeWeb News) — The synthetic biology company Verdezyne will develop novel genes for Syngenta, which will test them for enzyme expression in plants, Verdezyne said today.

Formerly called Coda Genomics, Verdezyne uses computational algorithms to design and synthesize gene libraries used to make proteins, metabolic pathways, and microorganisms, which are in turn used to make platform chemicals and biofuels.

Syngenta sells genetically modified plant seeds and biology-based crop protection technologies.

Financial terms of the agreement were not released.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.